Navigation Links
Simcere Pharmaceutical Group Announces Jiangsu Yanshen's Voluntary Suspension of Production
Date:12/2/2009

NANJING, China, Dec. 2 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group ("Simcere" or the "Company") (NYSE: SCR), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today reported that its subsidiary Jiangsu Yanshen Biological Technology Stock Co., Ltd. ("Jiangsu Yanshen") has suspended production of all its products in order to conduct an internal inspection and improve its quality control systems.

After obtaining a controlling stake in Jiangsu Yanshen on October 24, 2009, Simcere discovered quality control problems relating to the production of Yanshen's human-use rabies vaccine (vero cell). On November 23, 2009, Simcere urged the board of Jiangsu Yanshen to replace its general manager and head of quality assurance and demanded the company implement a total suspension of production effective on November 30, 2009 in order to facilitate internal inspection and rectification of its quality control systems. Jiangsu Yanshen reported the suspension to the relevant regulatory authorities and is actively coordinating with them on the matter.

Mr. Jinsheng Ren, Chairman and Chief Executive Officer of Simcere Pharmaceutical Group, commented: "The safety of our patients and customers has always been our priority and we have consistently worked to implement GMP management guidelines. The voluntary suspension of production at Jiangsu Yanshen as we implement an improved quality control system is consistent with our operating procedure for quality management."

Safe Harbor Statement

This press release contains forward-looking statements. These statements constitute "forward-looking" statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "anticipate," "believe," "estimate," "expect," "forecast," "intend," "may," "plan," "project," "predict," "should" and "will" and similar expressions. In particular, the quotations from management in this press release and the section under "Financial Outlook" contain forward-looking statements. These forward looking statements are based upon management's current views and expectations with respect to future events and are not a guarantee of future performance. Furthermore, these statements are, by their nature, subject to a number of risks and uncertainties that could cause actual performance and results to differ materially from those discussed in the forward-looking statements as a result of a number of factors. Further information regarding these and other risks is included in Simcere's filings with the U.S. Securities and Exchange Commission at www.sec.gov. Simcere does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

About Simcere Pharmaceutical Group

Simcere Pharmaceutical Group (SCR, Simcere) is a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China. In recent years, Simcere has been focusing its strategy on the development of innovative pharmaceuticals and first-to-market generics, and has introduced an innovative anti-cancer medication Endu, a first-to-market medication Sinofuan, and first-to-market generics such as Bicun and Anxin. Simcere manufactures and sells antibiotics, anti-cancer medication stroke management medication and biopharmaceutical drugs such as vaccines. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, orthopaedics and infectious diseases. For more information about Simcere Pharmaceutical Group, please visit http://www.simcere.com .

    For more information, please contact:

    Investor and Media Contacts:
     Email: ir@simcere.com

    In Nanjing:
     Frank Zhao
     Chief Financial Officer
     Simcere Pharmaceutical Group
     Tel: +86-25-8556-6666 ext 8818

    In Beijing:
     Ruirui Jiang
     Brunswick Group
     Tel: +86-10-6566-2256

   In the United States:
    Kate Tellier
    Brunswick Group
    Tel: +1-212-333-3810

   In Hong Kong:
    Joseph Lo Chi-Lun
    Brunswick Group
    Tel: +852-3512-5000

SOURCE Simcere Pharmaceutical Group


'/>"/>
SOURCE Simcere Pharmaceutical Group
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Simcere Pharmaceutical Group to Acquire Additional Stake in Jiangsu Yanshen Biological Technology Stock Co., Ltd.
2. Simcere Pharmaceutical Group Announces Collaboration with OSI Pharmaceuticals
3. Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study
4. Reportlinker Adds Latin American Pharmaceutical Market Outlook to 2014: Policy environment, market analysis, forecasts and growth opportunities
5. Reportlinker Adds Direct to Consumer (DTC) Advertising in Pharmaceuticals - Current and Future Market Outlook, Regulatory Landscape and Case Studies
6. Lilly Releases Latest Value of Medicine Resource Guide About Key Issues Facing the Pharmaceutical Industry
7. Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA New Product Approvals for 2 Generic Products
8. ADVENTRX Pharmaceuticals Reports Additional Pre-Clinical Data for ANX-514
9. Sagent Pharmaceuticals Bolsters Antibiotics Offering With Two Product Launches
10. Vanda Pharmaceuticals Announces Expiration of Hart-Scott -Rodino Waiting Period for Exclusive License of Fanapt(TM)
11. Pharmaceutical and Life Sciences Companies Face Rising Tax Rates, Says PricewaterhouseCoopers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... Mass. , March 22, 2017  Applied ... mechanistic modeling to drug research and development, today ... Day 2017.  QSP Day 2017 is a day ... the quantitative systems pharmacology (QSP) community. The focus ... modeling is de-risking and accelerating drug research and ...
(Date:3/22/2017)... March 22, 2017 Hologic, Inc. (Nasdaq: ... the acquisition of Cynosure, Inc., a leader in medical ... cash. "We are pleased to complete our ... Michael Davin and the entire Cynosure team ... growing medical aesthetics market," said Steve MacMillan , ...
(Date:3/22/2017)... YORK , March 22, 2017 ... (EP) market is growing rapidly due to the significant ... report published by Allied Market Research, the global electrophysiology ... expected to reach $8.271 billion by 2022, with a ... and is used to diagnose abnormal heartbeats or arrhythmia. ...
Breaking Medicine Technology:
(Date:3/22/2017)... ... March 22, 2017 , ... An intensive search of the medical literature has ... Norins, MD, PhD. He says investigating this possibility, is important because Miami-Dade ... in new infections with HIV. , His findings appear on Analizir.com. ...
(Date:3/22/2017)... MA San Antonio, TX (PRWEB) , ... March ... ... and ISO certified medical imaging core lab with extensive therapeutic experience and operational ... a multi-year phase II immuno-oncology clinical trial for the treatment of non-small cell ...
(Date:3/22/2017)... ... March 22, 2017 , ... The Jim ... regional families and business owners, is joining the Teen Recovery Solutions organization in ... area. , A growing number of Oklahoma teens and adolescents face problems from ...
(Date:3/22/2017)... ... 22, 2017 , ... College basketball surges to its peak during the March ... that is, recruiting people to be foster parents. Through a televised spot, Coach Self ... foster care due to abuse, neglect and other family challenges. People who respond to ...
(Date:3/22/2017)... ... ... Nearly a decade after it was first recommended that men over the ... to stir controversy. The US Preventative Services Task Force (USPSTF) issued a recommendation against ... news from a study published in JAMA Oncology suggests that more men ...
Breaking Medicine News(10 mins):